CIA
ARKG icon

Concurrent Investment Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Concurrent Investment Advisors’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-9,378
Closed -$270K – 995
2024
Q1 		$270K Sell
9,378
-1,656
-15% -$49.8K 0.01% 702
2023
Q4 		$362K Buy
+11,034
New +$300K 0.02% 588

Other funds holding ARKG

MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Concurrent Investment Advisors's ARKG Position: Q2 2024 in Review

Concurrent Investment Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2024, closing a stake of 9,378 shares — an estimated $270K sold.

Concurrent Investment Advisors first reported a position in ARKG in Q4 2023 and held it in 2 quarters. The position peaked at $362K in Q4 2023. 261 funds tracked by Wall St. Rank hold ARKG as of Q2 2024.

  • Concurrent Investment Advisors reported no remaining ARK Genomic Revolution ETF position as of Q2 2024 after selling out during the quarter.
  • Concurrent Investment Advisors sold 9,378 ARK Genomic Revolution ETF shares in Q2 2024, an estimated $270K.
  • Concurrent Investment Advisors first reported a position in ARK Genomic Revolution ETF in Q4 2023 and held it in 2 quarters.
  • Concurrent Investment Advisors's ARK Genomic Revolution ETF position peaked at $362K in Q4 2023.
  • 261 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2024.

Based on Concurrent Investment Advisors's 13F filing for Q2 2024, filed 30 Jul 2024.